Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Role of expanded hemodialysis in COVID-19: a case report.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Short-term clinical results when comparing expanded hemodialysis therapy versus online hemodiafiltration therapy
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Sieving coefficients of hemodialysis membranes
Visit resource site
PD
Simultaneous Optimization of Ultrafiltration and Solute Transport in Automated Peritoneal Dialysis (APD) - Bergling K et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Solute Transport in Hemodialysis: Advances and Limitations of Current Membrane Technology
Visit resource site
PD
Stakeholder Priorities for Remote Management in Peritoneal Dialysis - Subramanian L et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Standardization of Nomenclature for the Mechanisms and Materials Utilized for Extracorporeal Blood Purification
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Successful pregnancy in a hemodialysis patient with primary hyperoxaluria type 1
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Superior biocompatibility of regional citrate anticoagulation compared to heparin during expanded hemodialysis with Theranova membrane
Visit resource site
PD
Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration - Finkelstein F, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Synergy of sodium thiosulphate treatment and expanded hemodialysis in the management of calciphylaxis? A case report
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Synergy of sodium thiosulphate treatment and expanded hemodialysis in the management of calciphylaxis? A case report
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.